Inpharma Weekly

, Volume 1197, Issue 1, pp 5–6 | Cite as


‘real world’ outcomes and prescribing patterns
  • Amanda Cameron
Newsletter Article


The platelet glycoprotein IIb/IIIa antagonist abciximab [‘ReoPro’] has well established efficacy for preventing complications in patients undergoing percutaneous coronary intervention. Therefore, the debate as to whether abciximab should be the standard of care in this indication focuses mainly on economic factors. At the 4th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research [ Arlington, Virginia, US; May 1999 ], the cost effectiveness of abciximab was demonstrated in a US meta-analysis. In addition, several studies examined abciximab use in various ‘real-world’ settings, revealing practice patterns and clinical and economic outcomes in patients undergoing coronary interventions.


Percutaneous Coronary Intervention Abciximab Ischaemic Event Platelet Glycoprotein percutaneOUS Coronary Intervention Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1999

Authors and Affiliations

  • Amanda Cameron

There are no affiliations available

Personalised recommendations